Comparative Pharmacology
Head-to-head clinical analysis: TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 10 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 10 IN PLASTIC CONTAINER.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER vs TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% is a parenteral nutrition solution providing calories (dextrose), amino acids (for protein synthesis), and electrolytes for maintenance of acid-base balance and cellular function. Dextrose is metabolized to glucose, which undergoes glycolysis and oxidative phosphorylation. Amino acids are used for protein synthesis and as an energy source. Electrolytes correct or prevent deficiencies.
This combination product provides parenteral nutrition. Dextrose supplies calories and energy. Electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate) maintain fluid and electrolyte balance. Amino acids provide nitrogen for protein synthesis.
Intravenous infusion only. Adult dose determined by nutritional requirements and metabolic tolerance. Typical dose: 500-2000 mL/day infused continuously or intermittently, with dextrose dosage not exceeding 0.5 g/kg/h. Final concentration of dextrose and amino acids must be monitored.
Intravenous infusion: 500 mL to 2 L per day, typically at 42 mL/hour, providing 4.25% amino acids and 10% dextrose for parenteral nutrition.
None Documented
None Documented
Dextrose: rapid, minutes (insulin dependent); amino acids: 20-30 min for free pool turnover; electrolytes: distribution half-life 2-4 hours, elimination depends on renal function. Clinical: continuous infusion maintains steady state.
Not applicable as a single entity; components have independent kinetics: amino acids ~0.5-2 h (endogenous turnover), dextrose ~2 h (glucose), electrolytes follow renal clearance.
Primarily renal (glomerular filtration). Dextrose is completely metabolized; electrolytes (sodium, chloride, potassium, calcium, magnesium, acetate) are excreted via kidneys. Acetate is metabolized to bicarbonate. No significant biliary/fecal elimination.
Renal: >95% as unchanged amino acids, dextrose (metabolized to CO2 and water), and electrolytes. Fecal/biliary: negligible (<1%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution